Last Updated : January 7, 2025
Details
FilesGeneric Name:
regorafenib
Project Status:
Active
Therapeutic Area:
Metastatic osteosarcoma
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0374-000
Call for patient/clinician input closed:
NOC Status at Filing:
N/A
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
Indicated for the treatment of metastatic osteosarcoma in patients who received at least 1 prior line of therapy.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Submission received | October 18, 2024 |
|---|---|
| Review initiated | October 21, 2024 |
| Expert committee meeting (initial) | March 20, 2025 |
Files
Last Updated : January 7, 2025